Want to see JP:4554 full AI Analyst Report?
4554 Stock Chart & Stats
¥1863.00
-¥1.00(-0.05%)
At close: 4:00 PM EDT
¥1863.00
-¥1.00(-0.05%)
Day’s Range― - ―
52-Week Range¥1,366.00 - ¥2,559.00
Previous CloseN/A
Volume101.20K
Average Volume (3M)86.41K
Market Cap
¥48.52B
Enterprise Value¥78.17K
Total Cash (Recent Filing)¥10.89B
Total Debt (Recent Filing)¥29.62B
Price to Earnings (P/E)18.8
Beta0.82
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.61%
Share Statistics
EPS (TTM)98.82
Shares Outstanding26,541,100
10 Day Avg. Volume111,080
30 Day Avg. Volume86,410
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)0.80
Price to Sales (P/S)0.73
P/FCF Ratio9.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)107.2
Revenue Forecast (FY)¥63.00B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthFuji Pharma's ~17% revenue growth reflects sustained product demand and commercial execution in its prescription business. Durable top-line expansion supports reinvestment in R&D and manufacturing scale, underpinning multi-quarter growth prospects independent of short-term market swings.
Diversified Business Model (Branded + CDMO)A dual model—branded prescription sales plus CDMO manufacturing—smooths revenue volatility and monetizes manufacturing assets. Contract manufacturing provides recurring fee-based income and secular demand from pharma outsourcing, enhancing resilience across product lifecycle stages.
Improving Free Cash FlowImproved free cash flow and a stronger FCF-to-net-income ratio increase financial flexibility for capex, debt servicing, or shareholder returns. Strengthening cash conversion is a durable indicator of operational health and reduces reliance on external financing.
Bears Say
Rising LeverageAn increasing debt-to-equity trend raises financial risk and interest obligations, lowering buffer against revenue or margin shocks. Sustained leverage growth can constrain capital allocation, limit strategic flexibility, and amplify downside during cyclical or regulatory headwinds.
Margin VolatilityRecent declines and volatility in EBIT and net margins suggest pressure from pricing, mix, or cost increases. Persistent margin variability undermines profit predictability, reducing the firm's ability to consistently fund R&D, manufacturing upgrades, or absorb higher financing costs.
Weak Operating Cash ConversionOperating cash lagging net income implies possible working capital strain or reliance on non-cash earnings. Over time this can impair self-funding for growth and force incremental borrowing or equity issuance, especially problematic given the company’s rising leverage.
Fuji Pharma Co., Ltd. News
4554 FAQ
What was Fuji Pharma Co., Ltd.’s price range in the past 12 months?
Fuji Pharma Co., Ltd. lowest stock price was ¥1366.00 and its highest was ¥2559.00 in the past 12 months.
What is Fuji Pharma Co., Ltd.’s market cap?
Fuji Pharma Co., Ltd.’s market cap is ¥48.52B.
When is Fuji Pharma Co., Ltd.’s upcoming earnings report date?
Fuji Pharma Co., Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 90 days.
How were Fuji Pharma Co., Ltd.’s earnings last quarter?
Fuji Pharma Co., Ltd. released its earnings results on Aug 06, 2026. The company reported ¥43.36 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Fuji Pharma Co., Ltd. overvalued?
According to Wall Street analysts Fuji Pharma Co., Ltd.’s price is currently Overvalued.
Does Fuji Pharma Co., Ltd. pay dividends?
Fuji Pharma Co., Ltd. pays a Semiannually dividend of ¥26 which represents an annual dividend yield of 2.61%. See more information on Fuji Pharma Co., Ltd. dividends here
What is Fuji Pharma Co., Ltd.’s EPS estimate?
Fuji Pharma Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fuji Pharma Co., Ltd. have?
Fuji Pharma Co., Ltd. has 26,541,100 shares outstanding.
What happened to Fuji Pharma Co., Ltd.’s price movement after its last earnings report?
Fuji Pharma Co., Ltd. reported an EPS of ¥43.36 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.804%.
Which hedge fund is a major shareholder of Fuji Pharma Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4554
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fuji Pharma Co., Ltd.
Fuji Pharma Co., Ltd. is a pharmaceutical company that operates globally, focusing on the complete spectrum of drug development, from initial research and discovery through manufacturing and commercialization. Its comprehensive product line includes various medical solutions such as injectable medications, oral therapeutics, topical treatments, and a range of diagnostic tools. Beyond its core pharmaceutical offerings, Fuji Pharma also specializes in women's healthcare products, advanced in vitro diagnostic technologies, and acute medical intervention solutions. The company further contributes by disseminating valuable pharmaceutical and general health information. Founded in 1965, Fuji Pharma Co., Ltd. has its corporate headquarters located in Tokyo, Japan.
Technical Analysis
Mochida Pharmaceutical Co., Ltd.
―
Fuso Pharmaceutical Industries,Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Daito Pharmaceutical Co., Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―